Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02042014 | Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan | PHASE3 | COMPLETED | 8 | — | — | Jan 22, 2014 | Oct 17, 2016 | Jun 18, 2019 | 3 | Japan |
All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.
| Arm | Type | Description |
|---|---|---|
| QTI571 | EXPERIMENTAL | Participants will receive QTI571 during 3 years. |
| Name | Type | Description |
|---|---|---|
| QTI571 | DRUG | QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day. |
Inclusion Criteria: * patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan. * Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator. Exc...